Venture Funding Deals: BioNTech's Big Money Leads January Financings
Executive Summary
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
You may also be interested in...
Oculis Raises CHF20M To Advance Topical DME Therapy And Turn Swiss
Icelandic clinical stage biotech Oculis closes CHF20M ($20.3m) series B financing to advance development of its Phase IIb topical DME drug candidate, relocate to Switzerland and beef up its management team.
BioNTech Raises $270M Series A Round To Pursue FIPCO Model
German biotech BioNTech has raised $270m in a Series A round as it seeks to broaden its investor base and finance its ambition to be a global, fully integrated pharmaceutical company (FIPCO). In the past nine years the company has secured $950m – including a $180m seed financing in 2008, various research grants ($50m), and upfront and near-term milestone payments from partners ($450m).
Deals In Depth: February 2023
Two $1bn+ alliances were penned in February. Topping the list was a potential $1.16bn deal between AstraZeneca and KYM Biosciences (a joint venture company of Keymed Biosciences and Lepu Biopharma, of which Keymed owns 70%). Under the exclusive global agreement, AstraZeneca will develop, manufacture and commercialize CMG901, a Phase I antibody drug conjugate for the treatment of Claudin 18.2-positive solid tumors including gastric cancers.